Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.